Axovant’s Paul Korner Named Chief Medical Officer of Agile Therapeutics

Agile Therapeutics (NASDAQ: [[ticker:AGRX]]) has appointed Paul Korner to serve as its chief medical officer. He comes to the Princeton, NJ-based company from Axovant Gene Therapies, where he was senior vice president of clinical development & medical affairs. His experience also includes roles at Solvay Pharmaceuticals, Wyeth Research, Bayer, and Ferring Pharmaceuticals. Agile is preparing for the commercial launch of Twirla, a once-a-week contraceptive skin patch that the FDA approved in February.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.